Condition

Breast Cancer Metastatic clinical trials and research

• 37Clinical trials
• 12Countries

Newest Breast Cancer Metastatic clinical trials

All recruiting trials (37)

• Decision Support Tool for People with Advanced Breast Cancer

  This study tests a decision support tool called COAST to help people with stage IV breast cancer talk with their doctors and share treatment preferences.

  Recruiting at 3 sites Weill Medical College of Cornell University · Brooklyn, New York and 2 other locations · NCT07635147

• HER2-PET to Predict T-DXd Benefit in Advanced Breast Cancer

  This study tests whether HER2-PET imaging can help predict how well T-DXd will work for adults with advanced HER2-positive or HER2-low breast cancer receiving the drug.

  Recruiting Fudan University · Shanghai · NCT07586215

• Nutrition awareness for women after non-metastatic breast cancer

  This online program tests whether an educational brochure and short surveys can help women who have finished treatment for non-metastatic breast cancer recognize unhealthy processed foods and be willing to change their diet.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07389967

• Sapu003 with or without exemestane for advanced mTOR-sensitive solid tumors

  This phase 1b test will try weekly IV Sapu003, given with exemestane for HR+/HER2- breast cancer or alone for other mTOR-sensitive advanced tumors, to see if it's safe and how your body handles it.

  Recruiting Phase 1 Sapu Nano (Us) LLC · Adelaide · NCT07369505

• First-line Sacituzumab Govitecan for Advanced Untreated Triple-Negative Breast Cancer

  This study tests whether Sacituzumab Govitecan can slow disease progression when given as a first treatment to adults with advanced triple-negative breast cancer who have not yet received treatment in the advanced setting.

  Recruiting Phase 2 British Columbia Cancer Agency · Vancouver, British Columbia · NCT07299409

• OM-RCA-01 (anti-FGFR1 antibody) for metastatic tumors that express FGFR1

  This trial will try OM-RCA-01, an IV antibody given every two weeks, in adults with metastatic cancers whose tumors test positive for FGFR1 and who have progressed after standard treatments.

  Recruiting at 4 sites Phase 1/2 Kidney Cancer Research Bureau · Kazan' and 4 other locations · NCT07292168

• Fast detection of cancer in sentinel lymph nodes using a new NIR-II fluorescent probe.

  This test applies a new near-infrared (NIR-II) fluorescent probe to freshly removed sentinel lymph nodes to quickly tell adults with breast cancer whether the cancer has spread there.

  Recruiting Yunnan Cancer Hospital · Kunming, Yunnan · NCT07154563

• Avasopasem plus CDK4/6 inhibitor and hormonal therapy for metastatic HR+, HER2- breast cancer after progression

  This trial tests whether adding avasopasem to a CDK4/6 inhibitor and hormonal therapy is safe and may help people with metastatic HR+, HER2- breast cancer who progressed on prior CDK4/6 plus hormone therapy.

  Recruiting Phase 1 The University of Texas Health Science Center at San Antonio · San Antonio, Texas · NCT07137871

• Radiology-based prediction of HER2 level and T‑DXd benefit in metastatic breast cancer

  This study tests whether patterns in CT or FDG‑PET images can show HER2 level and help predict response to trastuzumab deruxtecan for people with metastatic breast cancer.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT07030569

• Evorpacept plus trastuzumab and chemotherapy for metastatic HER2‑positive breast cancer after trastuzumab‑deruxtecan

  This trial will test whether adding evorpacept to trastuzumab and chemotherapy helps people with metastatic HER2‑positive breast cancer whose disease progressed after trastuzumab‑deruxtecan.

  Recruiting at 60 sites Phase 2 ALX Oncology Inc. · Phoenix, Arizona and 60 other locations · NCT07007559

• Immune checkpoint washout for axillary lymph node staging in invasive ductal breast cancer

  This test sees if washing axillary lymph nodes for immune checkpoint markers can help find cancer spread in people with invasive ductal breast cancer who are scheduled for neoadjuvant therapy.

  Recruiting Istanbul Training and Research Hospital · Istanbul · NCT07003009

• Observing the effects of Sacituzumab Govitecan in metastatic breast cancer

  This study is testing how well Sacituzumab Govitecan works and how safe it is for people with metastatic HER-2 negative breast cancer who have already tried at least two other treatments.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT06966141

• 21-gene assay in elderly breast cancer patients with lymph node metastasis

  This study is trying to see how a special gene test can help doctors understand the risk of breast cancer coming back in older women who have had surgery for a specific type of breast cancer that has spread to their lymph nodes.

  Recruiting Qilu Hospital of Shandong University · Jinan, Shandong · NCT06891651

• Evaluating Circulating Tumor Cells in Breast Cancer Follow-up

  This study is testing a new way to track cancer cells in the blood of breast cancer patients to see how their condition changes during treatment.

  Recruiting ScreenCell · Neuilly-sur-Seine · NCT06807502

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

• Evaluating anticancer drug therapies for gynecologic and breast cancers

  This study is testing different cancer drug treatments to see how well they work and how well patients with breast and gynecologic cancers can tolerate them.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06800612

• Sacituzumab govitecan for HER2‑negative metastatic breast cancer in China

  This will test how well sacituzumab govitecan works and how safe it is for adults in China with HER2‑negative metastatic breast cancer.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06784921

• Testing for specific mutations in metastatic breast cancer patients using liquid biopsy

  This study is testing a new blood test to see if it can find specific gene mutations in people with certain types of metastatic breast cancer to help guide their treatment.

  Recruiting European Institute of Oncology · Milan, Italy · NCT06762483

• Testing a new drug for patients with metastatic HER2-negative breast cancer

  This study is testing a new drug called T-DXd to see if it can help adults with metastatic HER2-negative breast cancer feel better and improve their treatment outcomes.

  Recruiting at 3 sites Phase 2 Yale University · New Haven, Connecticut and 2 other locations · NCT06750484

• Imaging HER2-low breast cancers using a specialized PET scan

  This study is testing a new type of PET scan that uses a special version of a breast cancer drug to see if it can better find HER2-low breast cancers that might have been missed before.

  Recruiting Phase 1/2 Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Sherbrooke, Quebec · NCT06732336

• Combining SHR-A1811, Pyrotinib, and Bevacizumab for Advanced Breast Cancer with Brain Metastasis

  This study is testing a new combination of three drugs to see if it can help people with advanced breast cancer that has spread to the brain feel better and improve their treatment outcomes.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT06718933

• Imaging method for breast cancer using targeted PET scans

  This study is testing a new type of PET scan that targets specific proteins in breast cancer to see if it can help doctors better identify and understand the disease.

  Recruiting Phase 1/2 RenJi Hospital · Shanghai, Shanghai Municipality · NCT06715826

• Assessing PIK3CA mutations in metastatic breast cancer

  This study is testing a new way to find PIK3CA gene mutations in patients with metastatic breast cancer using both tissue samples and blood tests to see if it can help tailor treatments better.

  Recruiting European Institute of Oncology · Milan, MI · NCT06706570

• Detecting Tumor DNA in Blood to Find T-DXd Candidates in HR+/HER2-Low Metastatic Breast Cancer

  We test whether persistent tumor DNA in blood after starting standard therapy can identify HR+ HER2-low metastatic breast cancer patients who may benefit from trastuzumab deruxtecan.

  Recruiting at 12 sites Phase 2 Unicancer · Amiens and 39 other locations · NCT06680596

• Testing Abemaciclib with Radiation Therapy for Metastatic Breast Cancer

  This study is testing different doses of the drug abemaciclib in people with metastatic breast cancer who are also getting hormone therapy and radiation to see if it helps them better manage their symptoms.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06678269

• Evaluating drug sensitivity in organoids from breast cancer patients with fluid buildup

  This study is testing how well standard chemotherapy drugs work on lab-grown samples from breast cancer patients with fluid buildup to help personalize their treatment.

  Recruiting at 3 sites Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang and 2 other locations · NCT06658080

• Preventing neutropenia from sacituzumab govitecan in metastatic triple-negative breast cancer

  This trial tests sacituzumab govitecan given with pegfilgrastim to see if it prevents low white blood cell counts in people with metastatic triple-negative breast cancer who have had one or two prior chemotherapy regimens.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT06616987

• Evaluating Somatostatin Receptor Expression in Metastatic Breast Cancer Patients

  This study is testing if a special type of PET scan can help women with metastatic breast cancer see how their cancer is spreading and what treatment options might work best for them.

  Recruiting Phase 3 University Hospital, Grenoble · Grenoble · NCT06611891

• Combining TIL therapy and immunotherapy for advanced breast cancer

  This study is testing a new treatment that combines a special type of immune cell therapy with a drug called Pembrolizumab to see if it can help people with advanced breast cancer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06532812

• Sequential therapy for HER2-positive metastatic breast cancer

  This study is testing whether giving a specific order of HER2-targeted drugs can help people with HER2-positive metastatic breast cancer feel better and live longer.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06439693

• Exploring HER3-DXd treatment for advanced breast cancer

  This study is testing a new treatment called HER3-DXd, both alone and with another drug, to see if it can help people with advanced breast cancer that hasn't responded to previous treatments.

  Recruiting Phase 1/2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, France · NCT06298084

• Evaluating Bria-IMT with Checkpoint Inhibitor for Advanced Metastatic Breast Cancer

  This study is testing if a new treatment combining Bria-IMT with a checkpoint inhibitor can help people with advanced metastatic breast cancer live longer compared to other treatments their doctors might choose.

  Recruiting at 79 sites Phase 3 BriaCell Therapeutics Corporation · Phoenix, Arizona and 78 other locations · NCT06072612

• Targeting Integrin αvβ6 for PET Imaging in Cancer

  This study is testing a new imaging tool to see if it can help doctors better diagnose and stage certain cancers, like lung and breast cancer, by using a special scan that targets a specific protein found in tumors.

  Recruiting Zhongnan Hospital · Wuhan, Hubei · NCT05835570

• Combining PARP and CDK4/6 inhibitors with endocrine therapy for advanced breast cancer

  This study is testing a new combination of treatments for women with a specific type of advanced breast cancer to see if it helps them more than current options.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05759546

• Evaluating INX-315 for advanced cancer treatment

  This study is testing a new oral medication called INX-315 to see if it can safely help people with advanced cancers, including breast and ovarian cancer, who haven't responded to other treatments.

  Recruiting at 17 sites Phase 1/2 Incyclix Bio · Orlando, Florida and 17 other locations · NCT05735080

• Screening for Breast Cancer-Related Lymphedema in Targeted Therapy

  This study tests whether targeted breast cancer therapies are linked to lymphedema by tracking arm volume and symptoms in women undergoing treatment.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT05142800

• Treatment for metastatic cancer with BRCA or PALB2 mutations using chemotherapy and stem cells

  This study is testing a new treatment combining chemotherapy and stem cells for people with metastatic pancreatic or breast cancer who have BRCA or PALB2 mutations to see if it is safe and effective.

  Recruiting Phase 1 General Oncology, Inc. · Boston, Massachusetts and 1 other locations · NCT04150042

Related topics

Quick answers

How many Breast Cancer Metastatic clinical trials are recruiting right now?

37, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 12 countries. The most sites are in China (11 trials), United States (11 trials), Italy (6 trials), France (5 trials), Canada (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7, Phase 1/2: 7, Phase 1: 4, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →